Plasticity of lineage switch in B-ALL allows for successful rechallenge with CD19-directed immunotherapyBrittany M. Lee, Adam J. Lamble, Corinne Summers et al.|Blood Advances|2023Cited by 16
<i>CRLF2</i> -rearranged B-cell ALL with extramedullary lineage switch to AML following CD19-targeted therapySara Silbert, Nirali N. Shah, Mark A. Ahlman et al.|Journal for ImmunoTherapy of Cancer|2024Cited by 8
Harmonization on defining B‐cell recovery post CD19‐CAR T‐cell therapy in B‐cell acute lymphoblastic leukemia: An international consensus statementAdam J. Lamble, Nirali N. Shah, Sandra D. Bohling et al.|HemaSphere|2025Cited by 6
How Many Tests Does It Take to Diagnose a Triple-Hit B-Lymphoblastic Lymphoma? (Hint, It’s A Lot)M. Das, Karen M. Chisholm, Karen D. Tsuchiya et al.|Pediatric and Developmental Pathology|2023Cited by 0